ArticleArthritis research & therapy2019

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis.

Jeffrey R Curtis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.